Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Capital Leases: 2024

Historic Capital Leases for Axsome Therapeutics (AXSM) over the last 1 years, with Dec 2024 value amounting to $2.9 million.

  • Axsome Therapeutics' Capital Leases rose 58.59% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 58.59%. This contributed to the annual value of $2.9 million for FY2024, which is N/A change from last year.
  • Per Axsome Therapeutics' latest filing, its Capital Leases stood at $2.9 million for FY2024.
  • In the past 5 years, Axsome Therapeutics' Capital Leases ranged from a high of $2.9 million in FY2024 and a low of $2.9 million during FY2024.
  • For the 1-year period, Axsome Therapeutics' Capital Leases averaged around $2.9 million, with its median value being $2.9 million (2024).